| Ytd | 16.03% | |
| 1y | 23.58% |
| Open | 1.54 | Prev Close | 1.54 | Low | 1.52 | High | 1.56 | Mkt Cap | 74.82M |
| Vol | 69.90K | Avg Vol | 322.57K | EPS | -0.21 | P/E | N/A | Forward P/E | -0.06 |
| Beta | 0.77 | Short Ratio | 11.20 | Inst. Own | 21.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.76 | 200-d Avg | 1.51 | 1yr Est | 8.33 |
MNOV News
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report)'s stock price passed above its two hundred day mov
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are bot
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's r
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topl
MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyce
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-ma
Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to e
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction
A total of 234 participants were randomized to two treatment arms at clinical sites in the United St
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular ses
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN ra
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t
MediciNova (MNOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estim
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims co
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
LA JOLLA, Calif. , May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc. , a biopharmaceutical company t
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) crossed above its 200-day moving average during tr
Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings pa
HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNO
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t
Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Modera
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have received an average recommendation
MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are bo
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to e
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of pr
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t